MI
TVTX icon

Motiv8 Investments’s Travere Therapeutics TVTX Stock Holding History

Motiv8 Investments’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2 Buy
+49
New +$1.59K ﹤0.01% 783

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Motiv8 Investments's TVTX Position: Q4 2025 in Review

Motiv8 Investments opened a new position in Travere Therapeutics (TVTX) in Q4 2025: 49 shares worth $2. The stake represents ﹤0.01% of the portfolio and ranks #783 among its holdings.

278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Motiv8 Investments held 49 shares of Travere Therapeutics worth $2 as of Q4 2025.
  • Travere Therapeutics was a new Motiv8 Investments position in Q4 2025.
  • Travere Therapeutics made up ﹤0.01% of Motiv8 Investments's portfolio in Q4 2025, its #783 holding.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Motiv8 Investments's 13F filing for Q4 2025, filed 13 Feb 2026.